Capricor Therapeutics Under Investigation
Faruqi & Faruqi, LLP, a recognized leader in securities law, is currently undertaking an investigation regarding claims for investors associated with Capricor Therapeutics Inc. If you're among those who sustained significant losses in your investment, particularly exceeding $50,000, it’s vital that you seek guidance about the potential legal recourse available to you.
Understanding the Investigation
The investigation primarily stems from allegations suggesting that Capricor Therapeutics, known for its innovative therapies, may have misled investors. The focus is on the company's alleged failure to disclose critical information regarding its lead cell therapy candidate, deramiocel, aimed at treating cardiomyopathy related to Duchenne muscular dystrophy (DMD).
Impact of Misleading Statements
Statements made by the company highlighted its capability to secure a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). However, it seems that these claims might have been misleading, especially when critical data concerning the safety and effectiveness of deramiocel was withheld from investors.
Recent Developments
On July 11, 2025, Capricor disclosed that it had received a Complete Response Letter (CRL) from the FDA, which explicitly denied its BLA due to insufficient evidence of effectiveness and the necessity for additional clinical data. This letter signaled a turning point for many investors, resulting in a significant drop in the company's stock price.
Stock Price Fluctuations
After the announcement, shares of Capricor plummeted from $11.40 per share to $7.64 the following day, illustrating the profound impact such news can have on stock market performance. Investors who experienced such losses during this turbulent period should be aware of their rights.
Becoming a Lead Plaintiff
The role of lead plaintiff in a federal securities class action is crucial as this individual represents the interests of the entire class. Anyone wishing to consider this option should consult with legal counsel to understand the implications fully and determine the best course of action.
Contacting Legal Experts
If you have information relating to the actions and claims surrounding Capricor, or if you were a shareholder, it is advisable to contact legal specialists who can assess your circumstances. This includes whistleblowers, former employees, and any individual with relevant insights into the company's operations.
Next Steps for Investors
Investors are encouraged to stay vigilant and informed regarding their investments. Understanding the legal landscape and your rights as a shareholder is essential for safeguarding your interests. Faruqi & Faruqi can provide insights on how to proceed if you feel aggrieved by Capricor's actions.
Frequently Asked Questions
What is the focus of the investigation on Capricor Therapeutics?
The investigation looks into allegations that Capricor misled investors regarding the efficacy of its drug deramiocel and failing to disclose critical safety data.
How can I participate in the legal action against Capricor?
Investors can reach out to legal firms like Faruqi & Faruqi to discuss the potential of becoming a lead plaintiff in the class action.
What triggered the decline in Capricor's stock price?
A Complete Response Letter from the FDA denying the Biologics License Application led to a significant drop in Capricor's stock price.
Who can lend information about Capricor's conduct?
Anyone with knowledge about Capricor's operations or business practices, including former employees and shareholders, are encouraged to provide information.
What can I do if I experienced losses in Capricor?
If you suffered losses, it’s important to consult with legal experts to explore your rights and potential actions.
